Using M&A for Data Advantages Beyond Product Pipelines

The “datafication” of health care means traditional life sciences companies must examine how they position themselves for the future. “Datafication” is particularly important for generating the knowledge to enable precision medicine for patients and the clear economic evidence for reimbursement discussions. EY research suggests that among the topics that should be at the top of the C-suite agenda are which kinds of deals – and which partners – position life sciences companies for maximum growth in 2019 and the future.